母细胞瘤中MDM2过度表达与MDM2放大和BRAFV600E表达的关联
Konstantinos I Tosios1, Eleni-Marina Kalogirou2, Ioannis G Koutlas3
1Department of Oral Pathology & Medicine and Hospital Dentistry, School of Dentistry, National and Kapodistrian University of Athens, 11527 Athens, Greece.
International journal of molecular sciences
|February 24, 2024
概括
骨髓母细胞瘤是一种常见的瘤,经常复发. 准BRAF和MDM2 (人类小鼠双分钟2同类物) 是有前途的,特别是在野生类型的p53. 这项研究研究了乳腺母细胞瘤中的MDM2,发现过度表达与MAPK激活有关.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 病理学 病理学 病理学
背景情况:
- 骨髓母细胞瘤是最常见的牙瘤,其特点是局部侵略性行为和高复发率.
- 向治疗,特别是BRAF抑制,是由于BRAF V600E常见突变而导致的乳母细胞瘤的有希望的替代或补充治疗方法.
- 同步抑制BRAF和MDM2 (人类小鼠双分钟2同类物) 已在其他瘤中显示出增强的疗效,特别是野生型p53 (WTp53).
研究的目的:
- 为了研究MDM2蛋白表达和基因放大在乳腺母细胞瘤.
- 为了将MDM2表达与BRAF V600E和p53状态相关联.
- 探索双重BRAF/MDM2抑制的潜力,作为阿米洛母细胞瘤的治疗策略.
主要方法:
- 免疫组织化学被用于评估MDM2过度表达,BRAF V600E和p53表达在44例乳腺母细胞瘤病例中.
- 光 in situ 杂交 (FISH) 被用于评估MDM2基因多样性.
- 进行了统计分析,以确定这些标记物之间的关联.
主要成果:
- 在36.36%的乳腺母细胞瘤病例中观察到MDM2过度表达.
- 在MDM2过度表达的瘤中,43.75%是BRAF V600E阳性,93.75%是p53阴性 (WTp53).
- 过度表达MDM2与MDM2基因放大无关,这表明与MAPK激活有联系.
结论:
- 在乳腺母细胞瘤中MDM2过度表达可能与MAPK激活和WTp53表达有关,而不是基因放大.
- MDM2表达可以作为AMELOBLASTOMA中MAPK激活的标志物.
- 双重BRAF/MDM2抑制可能是一种可行的治疗方法,用于具有特定分子配置的乳腺母细胞瘤 (MDM2-过度表达/BRAFV600E阳性/WTp53).
相关概念视频
Abnormal Proliferation
4.5K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K
Mitogens and the Cell Cycle
6.5K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.5K


